Daily Brief Health Care: Acotec Scientific Holdings, Intuitive Surgical, GlaxoSmithKline PLC and more

In today’s briefing:

Acotec Scientific Holdings (6669.HK) – Logic Behind Boston Scientific’s Partial Offer and the Impact
Intuitive Surgical Inc.: Initiation of Coverage – Recent Approvals & Other Drivers
GlaxoSmithKline ADR: Initiation of Coverage – Business Strategy & Other Drivers

Acotec Scientific Holdings (6669.HK) – Logic Behind Boston Scientific’s Partial Offer and the Impact

Boston Scientific angles for majority stake with US$523 million for Acotec Scientific Holdings (6669HK), which is the largest acquisition of a Chinese medical device company by a MNC since 2014.
Completion of the Partial Offer would further strengthen Boston Scientific’s presence in China and create the potential for commercialization of Acotec products globally. It’s a win-win deal for both sides.
Companies listed in HKEX don’t have to seek valuation within HKEX system. If they can find “new anchor points”, they’ll have higher valuation.Chapter 18A companies’ future stock prices would diverge.

This is our first report on Intuitive Surgical, one of the largest players in robotic surgery offerings across the globe.
Korean growth remained steady, while Japanese procedure growth quickened compared to Q2.
We initiate coverage on the stock of Intuitive Surgical with a ‘Hold’ rating.

This is our first report on GlaxoSmithKline (GSK), one of the largest pharmaceutical companies in the world.
The company is making a significant performance in both operating performance and R&D productivity.
GSK continued disciplined cost control by prioritizing investments in the growth for supporting launches in Vaccines and Specialty Medicines, namely Shingrix.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network